---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-004102"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:24:44.011044+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro completes Phase IIA MAD trial for AL001; topline data due June 2023

## Summary
- Completed clinical portion of Phase IIA multiple ascending dose trial for AL001 in Alzheimer's dementia.
- AL001 is a novel lithium-delivery ionic cocrystal aiming to improve safety over current lithium treatments.
- Topline data from the MAD study expected in June 2023.
- Trial evaluated safety, tolerability, and maximum tolerated dose in mild-to-moderate Alzheimer's patients and healthy subjects.

## SEC filing metadata
- accession: 0001214659-23-004102
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465923004102/0001214659-23-004102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465923004102/r3212308k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-004102
- JSON: https://secwatch.observer/filing/0001214659-23-004102.json
- Plain text: https://secwatch.observer/filing/0001214659-23-004102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.